Letter re: Marr editorial

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 1038-1039

  Harris, J R ^a   Lockhart, S R ^a   Chiller, T ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOTHYMOL BLUE;

BACTERIAL STRAIN; BACTERIUM ISOLATION; CENTRAL NERVOUS SYSTEM; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DISEASE CONTROL; ENDEMIC DISEASE; EPIDEMIC; HUMAN; LETTER; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; SURVIVAL; UNITED STATES;

COMMUNICABLE DISEASES, EMERGING; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE;

EID: 84858124760     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir1019     Document Type: Letter

References (3)

1. Marr KA. Cryptococcus gattii: the tip of the iceberg. Clin Infect Dis 2011; 53:1196-8.
2. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188-95.
3. Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL, Wengenack NL. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol 2009; 47:3669-72.